



(51) International Patent Classification:

C12N 5/071 (2010.01) C12N 5/02 (2006.01)
C12Q 1/68 (2006.01) C07K 14/47 (2006.01)
C12N 5/0735 (2010.01) C07K 14/50 (2006.01)

(21) International Application Number:

PCT/US2011/036043

(22) International Filing Date:

11 May 2011 (11.05.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/333,831 12 May 2010 (12.05.2010) US

(71) Applicant (for all designated States except US): **CEN-
TOCOR ORTHO BIOTECH INC.** [US/US]; 800/850
Ridgeview Drive, Horsham, PA 19044 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **XU, Jean** [US/US];
199 Grandview Road, Skillman, NJ 08558 (US).

(74) Agents: **JOHNSON, Philip S.** et al.; Johnson & Johnson,
One Johnson & Johnson Plaza, New Brunswick, NJ
08933 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

[Continued on next page]

(54) Title: DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS

FIG. 3A

Secreting Human C-peptide - Kidney Capsule




FIG. 3B

Secreting Human C-peptide - Theraclyte





FIG. 3C

Secreting Human C-peptide - (12-week)



(57) Abstract: The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce a population of cells expressing markers characteristic of the pancreatic endoderm lineage, wherein greater than 50% of the cells in the population co-express PDX1 and NKX6.1.



-
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- Published:**
- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*